Ask AI
ProCE Banner Activity

HARMONi-6 Phase III Trial: OS Outcomes With 1L Ivonescimab + Chemotherapy vs Tislelizumab + Chemotherapy for Advanced Squamous NSCLC

Conference Coverage
Slideset

Results from the phase III HARMONi-6 trial showed clinically meaningful and statistically significant overall survival benefits with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy as first-line therapy in patients with stage IIIB-IV squamous NSCLC.

Released: June 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and PharmaMar.

Lilly

PharmaMar

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate pivotal ASCO 2026 lung cancer data and expert guidance to optimize biomarker-driven treatment selection, sequencing, and monitoring across disease stages

  • Apply prognostic and predictive biomarkers to accurately identify patients most likely to benefit from targeted, immunotherapy-based, and emerging treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for lung cancer to accelerate their effective incorporation into clinical practice